SCHEMBL775809

SCHEMBL775809

O=S(=O)(O)c1ccc(CCCF)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 9/20 0.47
TSHR P16473 3/20 0.46
F2 P00734 2/20 0.46
TMPRSS4 Q9NRS4 2/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
LMNA P02545 1/20 0.45
ALDH1A1 P00352 1/20 0.43
NT5E P21589 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
CA1 P00915 4/20 0.42
CA12 O43570 3/20 0.42
CA9 Q16790 3/20 0.42
CA4 P22748 2/20 0.42
CA6 P23280 2/20 0.42
CA5A P35218 2/20 0.42
CA7 P43166 2/20 0.42
CA14 Q9ULX7 2/20 0.42
CA5B Q9Y2D0 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4333544 0.94 CA2 (0.49) CA2TSHRF2TMPRSS4TP53
SCHEMBL776514 0.88 TSHR (0.48) CA2TSHRF2TMPRSS4TP53
SCHEMBL30446884 0.87 CA2 (0.57) CA2TSHRF2TMPRSS4TP53
SCHEMBL1804527 0.84 CA2 (0.52) CA2TSHRF2TMPRSS4TP53
SCHEMBL11583429 0.83 LMNA (0.56) CA2TSHRF2TMPRSS4TP53
SCHEMBL9386381 0.82 CA2 (0.50) CA2TSHRF2TMPRSS4TP53
SCHEMBL1807220 0.82 CA2 (0.53) CA2TSHRF2TMPRSS4TP53
SCHEMBL1808940 0.82 CA2 (0.48) CA2TSHRF2TMPRSS4TP53
SCHEMBL1727436 0.82 CA2 (0.69) CA2TSHRLMNAALDH1A1NT5E
SCHEMBL28596556 0.81 CA2 (0.54) CA2TSHRF2TMPRSS4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382322-A1 DIAGNOSTICS FOR DETECTING ECTO-5'-NUCLEOTIDASE (CD73) EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) 2025-12-18 US disclosed
EP-4479139-A1 DIAGNOSTICS FOR DETECTING ECTO-5'-NUCLEOTIDASE (CD73) Eberhard Karls Universität Tübingen Körperschaft des Öffentlichen Rechts Medizinische Fakultät (DE) 2024-12-25 EP disclosed
WO-2023156601-A1 DIAGNOSTICS FOR DETECTING ECTO-5'-NUCLEOTIDASE (CD73) Westfälische Wilhelms-Universität Münster (DE) 2023-08-24 WO disclosed
US-9343777-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2016-05-17 US disclosed
US-9252457-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2016-02-02 US disclosed
EP-2338059-B1 Ligands for aggregated tau molecules WISTA LAB LTD (SG) 2015-04-08 EP disclosed
US-8895313-B2 Ligands for aggregated tau molecules WISTA LABORATORIES LTD. (SG) 2014-11-25 US disclosed
US-8633337-B2 Method and synthesis GE HEALTHCARE LIMITED (GB) 2014-01-21 US disclosed
US-8506930-B2 Compounds having affinity for amyloid NIHON MEDI-PHYSICS CO., LTD. (JP) 2013-08-13 US disclosed
US-20130060064-A1 METHOD AND SYNTHESIS GE HEALTHCARE LIMITED (GB) 2013-03-07 US disclosed
US-20120070731-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2012-03-22 US disclosed
EP-2019103-B1 COMPOUND HAVING AFFINITY FOR AMYLOID NIHON MEDIPHYSICS CO LTD (JP) 2011-11-30 EP disclosed
US-20110171739-A1 LIGANDS FOR AGGREGATED TAU MOLECULES WISTA LABORATORIES LTD. 2011-07-14 US disclosed
EP-2338059-A1 LIGANDS FOR AGGREGATED TAU MOLECULES Wista Laboratories Ltd. (SG) 2011-06-29 EP disclosed
US-20100267952-A1 USE OF NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID, AND PROCESS FOR PRODUCTION OF THE SAME NIHON MEDI-PHYSICS CO., LTD. (JP) 2010-10-21 US disclosed
EP-2218463-A1 USE OF NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID, AND PROCESS FOR PRODUCTION OF THE SAME Nihon Medi-Physics Co., Ltd. (JP) 2010-08-18 EP disclosed
WO-2010034982-A1 LIGANDS FOR AGGREGATED TAU MOLECULES WISTA LABORATORIES LTD. (SG) 2010-04-01 WO disclosed
US-20090325065-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2009-12-31 US disclosed
US-20090252679-A1 Novel Compound Having Affinity for Amyloid NIHON MEDI-PHYSICS CO., LTD. (JP) 2009-10-08 US disclosed
EP-2019103-A1 NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID NIHON MEDI-PHYSICS CO., LTD. (JP) 2009-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110171739-A1 LIGANDS FOR AGGREGATED TAU MOLECULES MAPT, PRNP, MAP4 CA2 1520/4885TSHR 1746/4885F2 2039/4885
US-20130060064-A1 METHOD AND SYNTHESIS RNMT, GMPS, GDA CA2 4225/4885TSHR 1805/4885F2 4240/4885
US-20090252679-A1 Novel Compound Having Affinity for Amyloid APBA1, SAAL1, SLC43A1 CA2 2231/4885TSHR 1244/4885F2 2530/4885
US-20100267952-A1 USE OF NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID, AND PROCESS FOR PRODUCTION OF THE SAME APBA1, APP, SAAL1 CA2 1513/4885TSHR 1478/4885F2 1373/4885
US-20250382322-A1 DIAGNOSTICS FOR DETECTING ECTO-5'-NUCLEOTIDASE (CD73) NT5E, ENTPD5, ENTPD1 CA2 2585/4885TSHR 1837/4885F2 3153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.